S&P 500   4,356.45 (-1.22%)
DOW   34,297.73 (-0.19%)
QQQ   345.11 (-2.32%)
AAPL   159.78 (-1.14%)
MSFT   288.49 (-2.66%)
FB   300.15 (-2.77%)
GOOGL   2,538.70 (-2.96%)
AMZN   2,799.72 (-3.15%)
TSLA   918.40 (-1.25%)
NVDA   223.24 (-4.48%)
BABA   119.14 (-1.02%)
NIO   23.79 (-4.34%)
AMD   111.13 (-4.63%)
CGC   7.36 (-0.54%)
MU   80.72 (-2.69%)
GE   91.11 (-5.98%)
T   26.48 (+0.53%)
F   19.98 (-2.01%)
DIS   136.51 (-0.69%)
AMC   16.02 (-3.73%)
PFE   52.54 (+1.94%)
ACB   4.21 (-2.55%)
BA   204.10 (-0.05%)
S&P 500   4,356.45 (-1.22%)
DOW   34,297.73 (-0.19%)
QQQ   345.11 (-2.32%)
AAPL   159.78 (-1.14%)
MSFT   288.49 (-2.66%)
FB   300.15 (-2.77%)
GOOGL   2,538.70 (-2.96%)
AMZN   2,799.72 (-3.15%)
TSLA   918.40 (-1.25%)
NVDA   223.24 (-4.48%)
BABA   119.14 (-1.02%)
NIO   23.79 (-4.34%)
AMD   111.13 (-4.63%)
CGC   7.36 (-0.54%)
MU   80.72 (-2.69%)
GE   91.11 (-5.98%)
T   26.48 (+0.53%)
F   19.98 (-2.01%)
DIS   136.51 (-0.69%)
AMC   16.02 (-3.73%)
PFE   52.54 (+1.94%)
ACB   4.21 (-2.55%)
BA   204.10 (-0.05%)
S&P 500   4,356.45 (-1.22%)
DOW   34,297.73 (-0.19%)
QQQ   345.11 (-2.32%)
AAPL   159.78 (-1.14%)
MSFT   288.49 (-2.66%)
FB   300.15 (-2.77%)
GOOGL   2,538.70 (-2.96%)
AMZN   2,799.72 (-3.15%)
TSLA   918.40 (-1.25%)
NVDA   223.24 (-4.48%)
BABA   119.14 (-1.02%)
NIO   23.79 (-4.34%)
AMD   111.13 (-4.63%)
CGC   7.36 (-0.54%)
MU   80.72 (-2.69%)
GE   91.11 (-5.98%)
T   26.48 (+0.53%)
F   19.98 (-2.01%)
DIS   136.51 (-0.69%)
AMC   16.02 (-3.73%)
PFE   52.54 (+1.94%)
ACB   4.21 (-2.55%)
BA   204.10 (-0.05%)
S&P 500   4,356.45 (-1.22%)
DOW   34,297.73 (-0.19%)
QQQ   345.11 (-2.32%)
AAPL   159.78 (-1.14%)
MSFT   288.49 (-2.66%)
FB   300.15 (-2.77%)
GOOGL   2,538.70 (-2.96%)
AMZN   2,799.72 (-3.15%)
TSLA   918.40 (-1.25%)
NVDA   223.24 (-4.48%)
BABA   119.14 (-1.02%)
NIO   23.79 (-4.34%)
AMD   111.13 (-4.63%)
CGC   7.36 (-0.54%)
MU   80.72 (-2.69%)
GE   91.11 (-5.98%)
T   26.48 (+0.53%)
F   19.98 (-2.01%)
DIS   136.51 (-0.69%)
AMC   16.02 (-3.73%)
PFE   52.54 (+1.94%)
ACB   4.21 (-2.55%)
BA   204.10 (-0.05%)
NASDAQ:RGNX

REGENXBIO Stock Competitors

$26.11
-0.15 (-0.57%)
(As of 01/25/2022 04:00 PM ET)
Add
Compare
Today's Range
$24.26
$26.45
50-Day Range
$24.91
$34.78
52-Week Range
$24.14
$49.50
Volume
328,736 shs
Average Volume
417,152 shs
Market Capitalization
$1.12 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.92

REGENXBIO (NASDAQ:RGNX) Vs. DNLI, VIR, ABCM, FATE, KOD, SWTX, TWST, BCRX, RLAY, and IOVA

Should you be buying REGENXBIO stock or one of its competitors? The main competitors of REGENXBIO include Denali Therapeutics (DNLI), Vir Biotechnology (VIR), Abcam (ABCM), Fate Therapeutics (FATE), Kodiak Sciences (KOD), SpringWorks Therapeutics (SWTX), Twist Bioscience (TWST), BioCryst Pharmaceuticals (BCRX), Relay Therapeutics (RLAY), and Iovance Biotherapeutics (IOVA). These companies are all part of the "biological products, except diagnostic" industry.

REGENXBIO vs.

Vir Biotechnology (NASDAQ:VIR) and REGENXBIO (NASDAQ:RGNX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, earnings, analyst recommendations, valuation, risk, media sentiment, dividends, institutional ownership and profitability.

REGENXBIO received 382 more outperform votes than Vir Biotechnology when rated by MarketBeat users. Likewise, 68.86% of users gave REGENXBIO an outperform vote while only 51.61% of users gave Vir Biotechnology an outperform vote.

CompanyUnderperformOutperform
Vir BiotechnologyOutperform Votes
16
51.61%
Underperform Votes
15
48.39%
REGENXBIOOutperform Votes
398
68.86%
Underperform Votes
180
31.14%

REGENXBIO has higher revenue and earnings than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vir Biotechnology$76.37 million53.74-$298.67 million-$0.87-36.05
REGENXBIO$154.57 million7.22-$111.25 million-$5.17-5.05

Vir Biotechnology has a beta of -1.54, suggesting that its stock price is 254% less volatile than the S&P 500. Comparatively, REGENXBIO has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500.

Vir Biotechnology presently has a consensus price target of $97.50, suggesting a potential upside of 210.91%. REGENXBIO has a consensus price target of $54.00, suggesting a potential upside of 106.82%. Given Vir Biotechnology's higher probable upside, analysts plainly believe Vir Biotechnology is more favorable than REGENXBIO.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vir Biotechnology
1 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.33
REGENXBIO
0 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.57

Vir Biotechnology has a net margin of -35.98% compared to REGENXBIO's net margin of -228.08%. Vir Biotechnology's return on equity of -13.73% beat REGENXBIO's return on equity.

Company Net Margins Return on Equity Return on Assets
Vir Biotechnology -35.98% -13.73% -9.47%
REGENXBIO -228.08% -44.70% -26.35%

In the previous week, Vir Biotechnology had 7 more articles in the media than REGENXBIO. MarketBeat recorded 11 mentions for Vir Biotechnology and 4 mentions for REGENXBIO. REGENXBIO's average media sentiment score of 0.27 beat Vir Biotechnology's score of -0.01 indicating that REGENXBIO is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Vir Biotechnology
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral
REGENXBIO
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

56.6% of Vir Biotechnology shares are held by institutional investors. Comparatively, 78.5% of REGENXBIO shares are held by institutional investors. 30.9% of Vir Biotechnology shares are held by insiders. Comparatively, 12.4% of REGENXBIO shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

REGENXBIO beats Vir Biotechnology on 10 of the 18 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RGNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

REGENXBIO (NASDAQ:RGNX) vs. Its Competitors

TypeREGENXBIOBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$1.12B$2.84B$4.53B$6.78B
Dividend YieldN/A2.10%2.07%2.96%
P/E Ratio-5.057.6216.1518.41
Price / Sales7.222,450.665,656.93229.83
Price / CashN/A65.9161.0368.47
Price / Book2.594.217.428.77
Net Income-$111.25M$2.52M$98.30M$156.36M
7 Day Performance-0.91%-3.95%-4.45%-4.46%
1 Month Performance-24.93%-20.87%-14.90%-11.45%
1 Year Performance-41.96%-48.45%-22.42%-9.27%

REGENXBIO Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DNLI
Denali Therapeutics
2.2464 of 5 stars
$33.73
-3.1%
$92.14
-173.2%
-56.1%$4.12B$335.66M240.95291Analyst Revision
VIR
Vir Biotechnology
2.7848 of 5 stars
$31.36
-4.8%
$97.50
-210.9%
-18.9%$4.10B$76.37M-36.05327
ABCM
Abcam
1.5149 of 5 stars
$17.17
-3.6%
$23.00
-34.0%
-29.8%$3.93B$401.06M0.001,500Gap Up
FATE
Fate Therapeutics
2.5331 of 5 stars
$39.87
-0.9%
$103.13
-158.7%
-59.3%$3.81B$31.43M-18.81279Insider Selling
Gap Down
KOD
Kodiak Sciences
2.1017 of 5 stars
$59.96
-3.6%
$122.00
-103.5%
-62.2%$3.10BN/A-13.8572Insider Selling
News Coverage
Gap Down
SWTX
SpringWorks Therapeutics
1.9931 of 5 stars
$55.15
-0.9%
$117.50
-113.1%
-34.7%$2.72B$35M-25.1878Gap Down
TWST
Twist Bioscience
2.1448 of 5 stars
$53.22
-5.0%
$118.25
-122.2%
-70.7%$2.70B$132.33M-16.84525News Coverage
Gap Down
BCRX
BioCryst Pharmaceuticals
2.2042 of 5 stars
$14.65
-2.7%
$19.82
-35.3%
+54.8%$2.62B$17.81M-11.54246
RLAY
Relay Therapeutics
2.2048 of 5 stars
$22.26
-2.9%
$50.00
-124.6%
-62.8%$2.41B$82.65M0.002,020Gap Down
IOVA
Iovance Biotherapeutics
2.0167 of 5 stars
$14.66
-0.5%
$35.70
-143.5%
-69.0%$2.30BN/A-7.12241Gap Down
ADPT
Adaptive Biotechnologies
2.3098 of 5 stars
$15.71
-4.2%
$50.67
-222.5%
-75.8%$2.22B$98.38M-11.47622News Coverage
Gap Down
IBRX
ImmunityBio
1.4783 of 5 stars
$5.55
-2.9%
$25.00
-350.5%
N/A$2.21B$110K0.00171Gap Down
KYMR
Kymera Therapeutics
2.1132 of 5 stars
$39.76
-0.3%
$77.50
-94.9%
-49.6%$2.04B$34.03M-23.5375
EXAI
Exscientia
1.6667 of 5 stars
$17.13
-5.6%
$27.33
-59.6%
N/A$2.02B$12.42M0.00N/ANews Coverage
RXRX
Recursion Pharmaceuticals
1.9181 of 5 stars
$11.62
-1.5%
$33.67
-189.7%
N/A$1.96B$3.96M0.00218Gap Down
VALN
Valneva
0.9882 of 5 stars
$33.71
-6.1%
$36.00
-6.8%
N/A$1.77B$126.02M0.00500News Coverage
Gap Up
High Trading Volume
RVMD
Revolution Medicines
2.3998 of 5 stars
$22.25
-0.3%
$35.83
-61.0%
-48.3%$1.64B$42.98M-9.39125News Coverage
ALLO
Allogene Therapeutics
2.5655 of 5 stars
$11.36
-0.2%
$35.00
-208.1%
-63.1%$1.62BN/A-6.04265
SANA
Sana Biotechnology
1.4032 of 5 stars
$8.51
-5.9%
$38.50
-352.4%
N/A$1.61BN/A-0.92265Gap Down
VCEL
Vericel
1.8514 of 5 stars
$33.60
-1.0%
$58.75
-74.9%
-17.7%$1.57B$124.18M-3,360.00273Analyst Revision
News Coverage
Gap Down
TIL
Instil Bio
1.7531 of 5 stars
$11.87
-13.0%
$30.00
-152.7%
N/A$1.53B$140K0.00150Positive News
Gap Down
NSTG
NanoString Technologies
1.8731 of 5 stars
$33.19
-5.3%
$67.50
-103.4%
-55.7%$1.52B$117.32M-13.60579Gap Down
ATRA
Atara Biotherapeutics
1.8264 of 5 stars
$15.10
-2.9%
$30.60
-102.6%
-20.5%$1.34BN/A-4.17437News Coverage
ITOS
iTeos Therapeutics
2.2281 of 5 stars
$36.13
-1.6%
$50.50
-39.8%
+12.1%$1.27BN/A124.5962
KRYS
Krystal Biotech
2.4398 of 5 stars
$56.40
-1.2%
$114.00
-102.1%
-19.8%$1.25BN/A-20.8175Gap Down
EDIT
Editas Medicine
1.8962 of 5 stars
$18.23
-1.4%
$50.00
-174.3%
-71.9%$1.25B$90.73M-5.63235Gap Down
ALEC
Alector
2.8714 of 5 stars
$15.27
-4.3%
$41.40
-171.1%
-4.0%$1.24B$21.10M-29.36171
CCCC
C4 Therapeutics
2.2779 of 5 stars
$23.19
-3.4%
$48.50
-109.1%
-39.4%$1.13B$33.19M0.0099
SRNE
Sorrento Therapeutics
1.9917 of 5 stars
$3.51
-0.9%
$25.50
-626.5%
-63.3%$1.08B$39.99M-2.85502Gap Down
REPL
Replimune Group
2.3865 of 5 stars
$20.70
-2.4%
$55.25
-166.9%
-52.2%$970.69MN/A-10.67152Gap Down
INBX
Inhibrx
2.0531 of 5 stars
$25.52
-1.4%
$53.00
-107.7%
-29.0%$968.61M$12.89M-12.3388News Coverage
Gap Down
High Trading Volume
IMCR
Immunocore
1.5881 of 5 stars
$21.93
-1.4%
$54.75
-149.7%
N/A$945.78M$38.67M0.002,020Gap Down
PCVX
Vaxcyte
1.5798 of 5 stars
$17.91
-1.6%
N/A-27.6%$945.38MN/A-10.0158Gap Down
CHRS
Coherus BioSciences
2.2048 of 5 stars
$12.29
-3.7%
$25.75
-109.5%
-30.5%$943.69M$475.82M-3.91317
MOLN
Molecular Partners
1.3914 of 5 stars
$27.85
-2.5%
$27.38
-1.7%
N/A$899.33M$9.97M0.00152Gap Down
SOPH
SOPHiA Genetics
1.7 of 5 stars
$13.91
-6.6%
$23.00
-65.3%
N/A$881.03M$28.40M0.00N/ANews Coverage
Gap Down
High Trading Volume
SGMO
Sangamo Therapeutics
1.8731 of 5 stars
$5.97
-0.7%
$18.40
-208.2%
-60.3%$869.68M$118.19M-4.70413
IMVT
Immunovant
2.13 of 5 stars
$6.99
-0.7%
$15.00
-114.6%
-83.6%$803.85MN/A-5.5068
ADGI
Adagio Therapeutics
1.5215 of 5 stars
$6.74
-8.3%
$16.25
-141.1%
N/A$749.84MN/A0.002,021Gap Down
IPSC
Century Therapeutics
1.6248 of 5 stars
$13.15
-5.6%
$36.00
-173.8%
N/A$718.53MN/A0.00102Gap Down
AGEN
Agenus
1.9931 of 5 stars
$2.68
-0.4%
$11.50
-329.1%
-21.8%$688.31M$88.17M-22.33359Gap Down
OCGN
Ocugen
1.8914 of 5 stars
$3.38
-1.8%
$7.90
-133.7%
+52.3%$673.25M$42.62M0.0015Gap Down
MGTX
MeiraGTx
2.4514 of 5 stars
$14.98
-0.4%
$26.50
-76.9%
-3.8%$665.85M$15.56M-8.14219
ICVX
Icosavax
2.1181 of 5 stars
$16.72
-3.4%
$48.57
-190.5%
N/A$652.78MN/A0.002,021Lockup Expiration
Gap Down
RUBY
Rubius Therapeutics
2.0998 of 5 stars
$7.26
-6.1%
$26.00
-258.1%
-18.8%$652.43MN/A-3.42204News Coverage
Gap Down
CRBU
Caribou Biosciences
2.0715 of 5 stars
$10.64
-0.4%
$30.60
-187.6%
N/A$640.44MN/A0.002,021Gap Down
SRRK
Scholar Rock
2.3265 of 5 stars
$18.19
-1.9%
$54.33
-198.7%
-67.7%$638.62M$15.40M-5.33119News Coverage
Gap Down
IMTX
Immatics
1.7 of 5 stars
$9.97
-0.8%
$32.00
-221.0%
-10.1%$627.20M$35.70M0.002,020News Coverage
VXRT
Vaxart
1.7214 of 5 stars
$4.70
-1.7%
$13.75
-192.6%
-35.3%$589.83M$4.05M-8.7028
CGEM
Cullinan Oncology
2.3667 of 5 stars
$13.44
-1.0%
$51.75
-285.0%
-64.7%$587.13MN/A0.0024Gap Down
This page was last updated on 1/25/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.